CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.

doi:10.1007/s00401-016-1552-2

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.

Acta neuropathologica - 1 Jun 2016

Kang Ju-Hee, Mollenhauer Brit, Coffey Christopher S, Toledo Jon B, Weintraub Daniel, Galasko Douglas R, Irwin David J, Van Deerlin Vivianna, Chen-Plotkin Alice S, Caspell-Garcia Chelsea, Waligórska Teresa, Taylor Peggy, Shah Nirali, Pan Sarah, Zero Pawel, Frasier Mark, Marek Kenneth, Kieburtz Karl, Jennings Danna, Tanner Caroline M, Simuni Tanya, Singleton Andrew, Toga Arthur W, Chowdhury Sohini, Trojanowski John Q, Shaw Leslie M

Abstract excerpt

The development of biomarkers to predict the progression of Parkinson's disease (PD) from its earliest stage through its heterogeneous course is critical for research and therapeutic development. The Parkinson's Progression Markers Initiative (PPMI) study is an ongoing international multicenter, prospective study to validate biomarkers in drug-naïve PD patients and matched healthy controls (HC). We quantified...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid beta-Peptides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers

Share to Cognition

Share to Cognition Disorders

Share to Disease Progression

Share to Early Diagnosis

Share to Parkinson Disease

Share to Peptide Fragments

Source

Open in PubMed Open full text

Identifiers

PMID: 27021906
DOI: 10.1007/s00401-016-1552-2
PMCID: PMC5031365

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.PMID 27021906Read ↗

Plasma Biomarkers Differentiate Parkinson’s Disease From Atypical Parkinsonism SyndromesSemantic proximity Read ↗

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.Semantic proximity Read ↗

Changes in the cerebrospinal fluid proteome precede and stratify the course of Parkinson’s DiseaseSemantic proximity Read ↗

Parkinson’s disease causality and heterogeneity: a proteogenomic viewSemantic proximity Read ↗

An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia.Semantic proximity Read ↗

Differences in Blood and Cerebrospinal Fluid Between Parkinson’s Disease and Related DiseasesSemantic proximity Read ↗

Presence of cerebral amyloid modulates phenotype and pattern of neurodegeneration in early Parkinson's disease.Semantic proximity Read ↗

Parkinson’s disease causality and heterogeneity: a proteogenomic viewSemantic proximity Read ↗

Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.Semantic proximity Read ↗

Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s diseaseSemantic proximity Read ↗

A proteogenomic view of Parkinson’s disease causality and heterogeneitySemantic proximity Read ↗

CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.